Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
5
6
Next >
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
March 08, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
February 28, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
February 18, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
February 10, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
January 21, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2025
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
December 17, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
December 10, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
December 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
November 26, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
November 25, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
November 18, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
November 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
October 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
October 24, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
October 10, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Third Quarter Financial Results
October 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
September 25, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.